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Abstract
The Hippo pathway is involved in colorectal cancer (CRC) development and progression. The 
Hippo regulator Rassf1a is also involved in the Ras signaling cascade. In this work, we tested 
single nucleotide polymorphisms within Hippo components and their association with outcome in 
CRC patients treated with cetuximab. Two cohorts treated with cetuximab plus chemotherapy 
were evaluated (198 RAS wild-type (wt) patients treated with first-line FOLFIRI plus Cetuximab 
within the FIRE-3 trial and 67 Ras wt patients treated either with first-line mFOLFOX6 or SOX 
plus Cetuximab). In these two populations, Rassf1a rs2236947 was associated with overall 
survival, as patients with a CC genotype had significantly longer OS compared to those with CA 
or AA genotypes. This association was stronger in patients with left-side CRC [HR: 1.79 (1.01–
3.14); P=0.044 and HR: 2.83 (1.14–7.03); P=0.025, for Fire 3 and JACCRO cohorts, respectively]. 
Rassf1a rs2236947 is a promising biomarker for patients treated with cetuximab plus 
chemotherapy.
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Introduction
Salvador-Warts-Hippo pathway controls organ size by regulating tissue growth. In recent 
times, several studies have highlighted the implication of deregulated Hippo signaling in 
cancer development and progression1. This novel pathway acts as a complex tumor 
suppressor network controlling cell growth, proliferation, stem-cell maintenance and 
epithelium mesenchymal transition2. Hippo’s signaling core consists of a complex of 
kinases whose activation ultimately leads to the phosphorylation of the oncoproteins YAP 
and TAZ preventing their translocation to the nucleus. On the contrary, if YAP/TAZ are not 
phosphorylated they can translocate to the nucleus where they regulate the activity of several 
transcription factors that control the expression of the Hippo target genes. These target genes 
include amphiregulin, Sox2 or Birc5 among others. Additionally, Hippo pathway interacts 
with other pathways such as Wnt, TGFβ or Notch3. These pathways connections are of 
particular relevance for colorectal cancer (CRC) development and progression. Moreover, 
some of Hippo’s upstream regulators like Rassf1a are also crucial players in CRC. Rassf1a 
is a tumor suppressor that interacts with Ras signaling through a Ras interaction domain and 
with the Hippo pathway, specifically with MST, through a SARAH interaction domain. 
Rassf1a is also involved in microtubule stability, cell-cycle regulation and apoptosis4.
Rassf1a is methylated in a high percentage of CRC samples (12% to 81% depending on the 
series), representing an alternative mechanism of aberrant Ras signaling5 and, interestingly, 
a mutually exclusive relationship with KRAS mutations has been reported6, 7. Rassf1a has 
also been found to regulate the EGFR ligand amphiregulin by Hippo activation8.
The growing interest in the Hippo pathway in cancer is slowly translating into multiple 
translational research works that underscore the clinical relevance of this pathway in CRC 
tumors. The expression of Hippo’s oncoproteins YAP and TAZ has been correlated with the 
prognosis of CRC patients. A potential explanation for this correlation could be that 
TAZ/YAP signaling contributes to chemoresistance conferring cancer stem cell-related 
traits9, 10. Recently, in colon cancer cell lines YAP was reported to contribute to 5-
Fluorouracil (5-Fu) resistance by inducing cellular quiescence as well as contributing to a 
stem cell-like phenotype11. Not only the expression of YAP and TAZ appear to be useful in 
predicting the patients’ prognosis in CRC. Single nucleotide variations within genes 
involved in the Hippo pathway have also been investigated as biomarkers in colorectal 
cancer patients. In stages II and III colorectal cancer polymorphisms located within TAZ and 
Rassf1a were found to be associated with the recurrence risk12. However, in the metastatic 
colorectal cancer (mCRC) setting to our knowledge genetic variants within genes involved 
in the Hippo pathway have not been evaluated. In mCRC, a combination of anti-EGFR 
therapies plus chemotherapy is considered a standard of care in Ras wild-type patients13–16. 
Despite of the presence of Ras mutations as strong biomarkers to select the patients that 
benefit the most from anti-EGFR, approximately 25–30% of the patients do not respond to 
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treatment and, moreover, survival among responders can vary significantly. The mechanisms 
for this lack of response and survival differences remain unknown. We hypothesized that the 
critical role of the Hippo pathway in CRC development and progression might play a role in 
these differences. In this work, we evaluated single nucleotide polymorphisms within the 
Hippo pathway as biomarkers in mCRC patients treated with cetuximab plus chemotherapy.
Material and Methods
Selected polymorphisms
A total of 4 single nucleotide polymorphisms (SNPs) were selected based on previously 
reported results and based on their potential relevance in cetuximab treated patients12. The 
selected polymorphisms were: rs2073498 and rs2236947 located in the Rassf1 gene, 
rs558614 located in the LATS2 gene and rs3811715 located in the TAZ gene (also known as 
WWTR1). Rassf1 rs2073498 polymorphism is a missense change (Ala133Ser) located in 
exon 3. LATS2 rs558614 polymorphism is also a missense change (Ala324Val) located in 
exon 4. The rest of the analyzed polymorphisms are located intronically.
DNA was extracted from FFPE tissue samples and genotypes were obtained using PCR-
based direct sequencing. 5% of the samples were re-sequence to ensure the accuracy of the 
results revealing a concordance higher than 99%. The author that performed the genotyping 
was blinded to the clinical data set.
Patients’ clinical characteristics
These 4 SNPs were tested first in cohort 1 that comprised of all Ras wild-type patients 
enrolled in the arm A of Fire 3 trial. Those SNPs significantly associated with survival were 
subsequently evaluated in an independent cohort 2 that included all Ras wild-type patients 
enrolled in JACCRO 05 and JACCRO 06 trials.
Cohort 1 consisted of a total of 199 Ras wild-type patients enrolled in the arm A of Fire 3 
trial (NCT00433927) treated with FOLIRI plus cetuximab. Cohort 2 consisted of a total of 
67 patients enrolled in JACCRO 05 (UMIN000004197) or 06 (UMIN000007022) who 
received oxaliplatin based chemotherapy (FOLFOX or SOX) plus cetuximab. The clinical 
characteristics of these two cohorts have been described in detail somewhere else13, 17, 18. 
Table 1 describes the baseline clinical characteristics of the patients included in the study.
This study was performed following the REMARK recommendations for the reporting of 
biomarkers19. The study was approved by the ethics committees and all patients signed an 
informed consent.
Statistical analysis
The endpoints of the current study included overall survival (OS), progression-free survival 
(PFS), and tumor response per RECIST 1.0. Overall survival was measured as the time 
period from randomization or registration to death from any cause. PFS was defined as the 
time from the date of randomization in FIRE 3 and registration in JACCRO 05 or 06 to 
disease progression or death from any cause. PFS and OS were censored at the last follow-
up if progression and death were not observed.
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Deviations from distribution of the Hardy-Weinberg equilibrium were examined using χ2 
test. The true inheritance mode of the candidate polymorphisms had not been known yet, 
therefore a codominant, dominant or recessive model was assumed whenever appropriate. 
The associations of the SNPs and PFS or OS were analyzed using Kaplan Meier curves and 
log-rank tests. In the multivariable Cox regression analysis, the model was adjusted by 
baseline prognostic factors. The associations between the SNPs and tumor responses were 
examined using χ2 tests.
All analyses were conducted using SAS statistical package version 9.4 (SAS Institute, Cary, 
NC, USA). All tests were 2-sided at a significance level of 0.05. P values were adjusted for 
multiple testing using the false discovery rate (FDR). The FDR-adjusted P values <15% 
were considered as statistically significant.
Results
The median follow up for cohort 1 was 34.1 months (range 0.03–70.8) and the median 
overall survival reached 33.1 months. For the JACCRO 05 and 06 cohort, the median follow 
up was 31.6 months (range 5.5–42.9) and the median survival was 33.9 months.
Of all the analyzed samples, genotypes were achieved in at least 90% of the cases for each 
polymorphism. In those failed cases, genotypes were not obtained due to a limited DNA 
quantity or poor DNA quality.
The four analyzed polymorphisms were within the probabilities limits of the Hardy-
Weinberg equilibrium (p>0.05). For the Fire 3 cohort, the minor allele frequency was 47% 
and for the Japanese cohort 27% (expected 46% and 21% respectively, according to 
www.Ensembl.org).
In cohort 1, the rs2236947 polymorphism was associated with overall survival. In the 
dominant model, patients with a CC genotype had a median overall survival (OS) of 46.3 
months (95% CI; 21.8–70.8), whereas patients with a CA or AA genotypes had a median OS 
of 30.6 (95% CI, 23.9–38.3); P= 0.023. In the multivariable Cox regression model adjusting 
for sex, ECOG performance status (0 vs 1–2) and primary tumor site (right, left vs NA) and 
number of metastatic sites (1–2 vs 3 or more) the hazard ratio (HR) was 1.50 (95% CI, 0.94–
2.38); P=0.088. This SNP did not associate with the response rate (RR) or the progression-
free survival (PFS) in this population.
The rest of the analyzed polymorphisms did not yield any association regarding RR, PFS or 
OS. Table 2 shows in detail all the analyzed associations.
The rs2236947 located in the Rassf1a gene was analyzed in the second cohort of patients. In 
this population, the rs2236947 was also associated with OS: patients harboring a CC 
genotype had a median OS of 42.8 months (95% CI, 27.1–42.8) compared with the patients 
with a CA or AA genotypes whose median OS was 19.0 months (95% CI, 13.4–42.9); 
P=0.057. In the multivariable Cox regression model adjusting for ECOG performance status 
the HR was 2.72 (95% CI, 1.23–6.04); P=0.014. In this cohort, an association was found 
also regarding PFS. Table 3 shows in detail these results.
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These polymorphisms were also evaluated in an exploratory cohort of 190 patients enrolled 
in the arm B of the FIRE 3 arm and treated with FOLFIRI plus Bevacizumab. In this 
population no associations were found regarding response, PFS or OS based on the 
rs2236947 genotype (Online only Supplementary Table 1).
Subgroup analysis
The association of Rassf1a rs2236947 with OS was stronger in patients bearing left-side 
tumors. In cohort 1, patients with a CC genotype had a median OS of 59.0 months (95% CI, 
23.8–70.8) compared to 38.3 (95% CI, 29.8–41.2) months for the patients with a CA or AA 
genotypes, P=0.013. In multivariable analysis this association remained statistically 
significant with a HR of 1.79 (1.01–3.14); P=0.044 (Figure 1, Table 4). No association was 
found regarding Rassf1a rs2236947 genotype in patients harboring right-side colon tumors.
In cohort 2, patients harboring a CC genotype had a median OS of 42.8 months (95% CI, 
30.5–42.8) whereas patients with a CA or AA genotypes had a median OS of 23.2 (13.4–
42.9), P=0.056. In the multivariable analysis the HR was 2.83 (1.14–7.03); P=0.025 (Figure 
2, Table 3).
In this cohort, the rs2236947 SNP was also associated with PFS in patients harboring left-
side tumors. Patients with a CC genotype had a median PFS of 15.2 months (95% CI, 8.8–
18.0) compared to 10.0 months (95% CI, 8.5–11.7) for the patients with a CA or AA 
genotype, P=0.059. In multivariable analysis the HR was 1.98 (95% CI, 1.02–3.84); 
P=0.045.
Discussion
The polymorphism rs2236947 located in the Rassf1 gene was found to be associated with 
overall survival in two independent cohorts of patients treated with chemotherapy plus the 
anti-EGFR monoclonal antibody cetuximab. Moreover, this association appears to be 
stronger in patients bearing left-sided tumors. Additionally, in the JACCRO population this 
SNP was also associated with progression-free survival.
Rassf1a is a tumor suppressor frequently methylated in colorectal cancer. Rassf1a is 
involved not only in Ras signaling, but also it is a recognized upstream regulator of Hippo 
signaling interacting with MST through its SARAH domain5. The critical importance of Ras 
signaling in mCRC is widely known20. Regarding Hippo signaling, several recent works are 
highlighting influence of Hippo not only in the prognosis of CRC patients21, 22, but also in 
the lack of response to chemotherapy by favoring stemness and quiescence status of tumor 
cells23, 24. Moreover, recent works have associated Hippo’s oncogene YAP1 activation with 
resistance to cetuximab treatment25.
The signaling of Rassf1a through Ras and Hippo pathways make this protein an attractive 
drug candidate, particularly, to influence outcome in those patients treated with anti-EGFR 
therapies. Until now, polymorphisms within the Rassf1 gene had never been evaluated as 
predictive or prognostic marker in patients treated with anti-EGFR therapies. In a previous 
work, our group studied several SNPs within the Hippo pathway as recurrence predictors for 
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patients with high-risk stage II and stage III colon cancer. Interestingly, in this work the 
rs2236947 polymorphism correlated with recurrence-free probability at 3 years after surgery. 
Patients with an AA genotype had significantly higher recurrence rate12. This result is in 
keeping with the present work in which, patients with at least an A allele for the rs2236947 
SNP had significantly shorter OS compared to those patients with a CC genotype.
The association of rs2236947 with OS was significantly stronger in patients harboring left-
sided colorectal tumors. Over the past few years, mounting evidence is appearing regarding 
the differences between left and right colon cancer26–28. Particularly, in mCRC tumor 
location appears to have a strong implication in the patients’ prognosis as well as in the 
benefit derived from targeted therapies. It has been suggested that left side colon cancer 
location might be a predictor of cetuximab efficacy29, 30. In our study, the fact that value to 
predict survival for rs2236947 polymorphism was stronger in patients with left-sided 
colorectal tumors could be associated to these molecular differences. Rassf1a is implicated 
in Ras signaling, and Ras signaling is of high relevance for cetuximab efficacy. Therefore we 
hypothesize this is the reason for an association of rs2236947 with outcome only in left-side 
colorectal cancer patients. Nonetheless, due to the low number of patients with right-sided 
tumors we cannot firmly conclude that this SNP has no value in this population.
Overall, this study reveals a promising new biomarker for patients treated with 
chemotherapy plus cetuximab regardless of the chemotherapy backbone. Additionally, the 
value of rs2236947 as a biomarker could be confirmed in two different populations, 
Caucasian and Japanese, despite of the different minor allele frequencies. However, this 
work also has some limitations. First, the biological mechanism behind the association of 
Rassf1a rs2236947 with OS is not understood. This SNP is located intronically and its 
functionality is not known. This SNP is in high linkage disequilibrium with a missense 
polymorphism (rs13100173) located in the HYAL3 gene. However, whether this SNP can 
explain the association found is unknown. Nonetheless, in silico analysis using data from the 
ENCODE project31 has revealed a potential functionality for rs2236947 by affecting 
transcriptional regulation and the expression of target genes (www.Regulomedb.org)32. 
Second, although the SNP did not associate with response, in the Japanese cohort was also 
associated with PFS whereas no association was found in the FIRE 3 population. In the 
FIRE 3 trial no association with PFS was found when comparing the cetuximab and the 
bevacizumab arms13.
We believe that further evaluations of the rs2236947 polymorphism in independent cohorts 
as well as functionality studies are needed to confirm the prognostic/predictive value of 
Rassf1a rs2236947.
Supplementary Material
Refer to Web version on PubMed Central for supplementary material.
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figure 1. 
Rassf1a rs2236947 is associated with OS in Ras wt left-sided mCRC patients treated with 
FOLFIRI plus cetuximab in Fire 3.
*Wald test in the multivariable Cox Regression model adjusting for sex, ECOG, and number 
of metastatic sites
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figure 2. 
Rassf1a rs2236947 is associated with OS in Ras wt left-sided mCRC patients treated with 
oxaliplatin-based chemotherapy plus cetuximab.
*Wald test in the multivariable Cox Regression model adjusting for ECOG and regime 
(FOLFOX vs SOX).
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Table 1
Baseline characteristics of the two cohorts
Cohort 1: Fire-3 Arm A Cohort 2: JACCRO 05 and 06
N=297 % N=77 %
Age, years
Median (range) 64 (38–79) 63 (39–79)
  ≤65 158 53.2 45 58.4
  > 65 139 46.8 32 41.6
Sex
  M 213 71.7 44 57.1
  F 84 28.3 33 42.9
ECOGPS
  0 154 51.8 69 89.6
  1–2 143 48.2 8 10.4
Primary tumor site
  Right 54 18.2 11 14.3
  Left 236 79.5 64 83.1
  Unknown 7 2.4 2 2.6
Metastatic sites, n
  1 123 41.4 33 42.9
  >1 174 58.6 44 57.1
Time to mets
  Synchronous 217 74.3 59 76.6
  Metachronous 75 25.7 18 23.4
  Unknown 5
Adjuvant therapy
  No 226 77.4 71 92.2
  Yes 66 22.6 6 7.8
  Unknown 5
Mutation Status
  All RAS wildtype 199 83.6 67 87.0
  Mutant 39 16.4 10 13.0
  Unknown 59
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